Jill Roberts Center for Inflammatory Bowel Disease
Found 37 results
Author Title Type [ Year(Desc)]
Filters: First Letter Of Last Name is J  [Clear All Filters]
2001
Stathopoulos C, Jacquin-Becker C, Becker HD, Li T, Ambrogelly A, Longman R, Söll D.  2001.  Methanococcus jannaschii prolyl-cysteinyl-tRNA synthetase possesses overlapping amino acid binding sites.. Biochemistry. 40(1):46-52.
2004
Longman RS, Talal AH, Jacobson IM, Albert ML, Rice CM.  2004.  Presence of functional dendritic cells in patients chronically infected with hepatitis C virus.. Blood. 103(3):1026-9.
2005
Longman RS, Talal AH, Jacobson IM, Rice CM, Albert ML.  2005.  Normal functional capacity in circulating myeloid and plasmacytoid dendritic cells in patients with chronic hepatitis C.. J Infect Dis. 192(3):497-503.
2008
Sandborn WJ, Feagan BG, Fedorak RN, Scherl E, Fleisher MR, Katz S, Johanns J, Blank M, Rutgeerts P.  2008.  A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease.. Gastroenterology. 135(4):1130-41.
2011
Verma HDev, Scherl EJanice, Jacob VElizabeth, Bosworth BPaul.  2011.  Anti-nuclear antibody positivity and the use of certolizumab in inflammatory bowel disease patients who have had arthralgias or lupus-like reactions from infliximab or adalimumab.. J Dig Dis. 12(5):379-83.
2013
Dogan B, Scherl E, Bosworth B, Yantiss R, Altier C, McDonough PL, Jiang Z-D, Dupont HL, Garneau P, Harel J et al..  2013.  Multidrug resistance is common in Escherichia coli associated with ileal Crohn's disease.. Inflamm Bowel Dis. 19(1):141-50.
Kothary V, Scherl EJ, Bosworth B, Jiang Z-D, Dupont HL, Harel J, Simpson KW, Dogan B.  2013.  Rifaximin resistance in Escherichia coli associated with inflammatory bowel disease correlates with prior rifaximin use, mutations in rpoB, and activity of Phe-Arg-β-naphthylamide-inhibitable efflux pumps.. Antimicrob Agents Chemother. 57(2):811-7.
Montrose DC, Scherl EJ, Bosworth BP, Zhou XKathy, Jung B, Dannenberg AJ, Hla T.  2013.  S1P₁ localizes to the colonic vasculature in ulcerative colitis and maintains blood vessel integrity.. J Lipid Res. 54(3):843-51.
2015
Chen HJoyce, Sun J, Huang Z, Hou H, Arcilla M, Rakhilin N, Joe DJ, Choi J, Gadamsetty P, Milsom J et al..  2015.  Comprehensive models of human primary and metastatic colorectal tumors in immunodeficient and immunocompetent mice by chemokine targeting.. Nat Biotechnol. 33(6):656-60.
Gerbarg PL, Jacob VE, Stevens L, Bosworth BP, Chabouni F, DeFilippis EM, Warren R, Trivellas M, Patel PV, Webb CD et al..  2015.  The Effect of Breathing, Movement, and Meditation on Psychological and Physical Symptoms and Inflammatory Biomarkers in Inflammatory Bowel Disease: A Randomized Controlled Trial.. Inflamm Bowel Dis. 21(12):2886-96.
Kiuru M, Camp B, Adhami K, Jacob V, Magro C, Wildman H.  2015.  Treatment of metastatic cutaneous Crohn disease with certolizumab.. Dermatol Online J. 21(11)
2017
Battat R, Kopylov U, Bessissow T, Bitton A, Cohen A, Jain A, Martel M, Seidman E, Afif W.  2017.  Association Between Ustekinumab Trough Concentrations and Clinical, Biomarker, and Endoscopic Outcomes in Patients With Crohn's Disease.. Clin Gastroenterol Hepatol. 15(9):1427-1434.e2.
Viladomiu M, Kivolowitz C, Abdulhamid A, Dogan B, Victorio D, Castellanos JG, Woo V, Teng F, Tran NL, Sczesnak A et al..  2017.  IgA-coated enriched in Crohn's disease spondyloarthritis promote T17-dependent inflammation.. Sci Transl Med. 9(376)
Jacob V, Crawford C, Cohen-Mekelburg S, Viladomiu M, Putzel GG, Schneider Y, Chabouni F, OʼNeil S, Bosworth B, Woo V et al..  2017.  Single Delivery of High-Diversity Fecal Microbiota Preparation by Colonoscopy Is Safe and Effective in Increasing Microbial Diversity in Active Ulcerative Colitis.. Inflamm Bowel Dis. 23(6):903-911.
2018
Borges LF, Jagadeesan V, Goldberg H, Gavini S, Lo W-K, Burakoff R, Feldman N, Chan WW.  2018.  Abnormal Bolus Reflux Is Associated With Poor Pulmonary Outcome in Patients With Idiopathic Pulmonary Fibrosis.. J Neurogastroenterol Motil. 24(3):395-402.
Dulai PS, Boland BS, Singh S, Chaudrey K, Koliani-Pace JL, Kochhar G, Parikh MP, Shmidt E, Hartke J, Chilukuri P et al..  2018.  Development and Validation of a Scoring System to Predict Outcomes of Vedolizumab Treatment in Patients With Crohn's Disease.. Gastroenterology. 155(3):687-695.e10.
Dogan B, Belcher-Timme HFacey, Dogan EI, Jiang Z-D, Dupont HL, Snyder N, Yang S, Chandler B, Scherl EJ, Simpson KW.  2018.  Evaluation of Escherichia coli pathotypes associated with irritable bowel syndrome.. FEMS Microbiol Lett. 365(22)
Ghosh G, Jacob V, Wan D.  2018.  Plasmablastic Lymphoma in a Patient With Crohn's Disease After Extensive Immunosuppressive Therapy.. Clin Gastroenterol Hepatol. 16(4):e41-e42.
Battat R, Duijvestein M, Casteele NVande, Singh S, Dulai PS, Valasek MA, Mimms L, McFarland J, Hester KD, Renshaw M et al..  2018.  Serum Concentrations of 7α-hydroxy-4-cholesten-3-one Are Associated With Bile Acid Diarrhea in Patients With Crohn's Disease.. Clin Gastroenterol Hepatol.
2019
Battat R, Ma C, Jairath V, Khanna R, Feagan BG.  2019.  Benefit-Risk Assessment of Vedolizumab in the Treatment of Crohn's Disease and Ulcerative Colitis.. Drug Saf. 42(5):617-632.
Battat R, Dulai PS, Casteele NVande, Evans E, Hester KD, Webster E, Jain A, Proudfoot JA, Mairalles A, Neill J et al..  2019.  Biomarkers Are Associated With Clinical and Endoscopic Outcomes With Vedolizumab Treatment in Ulcerative Colitis.. Inflamm Bowel Dis. 25(2):410-420.
Lukin DJ, Lawlor G, Hudesman DP, Durbin L, Axelrad JE, Passi M, Cavaliere K, Coburn E, Loftus M, Jen H et al..  2019.  Escalation of Immunosuppressive Therapy for Inflammatory Bowel Disease Is Not Associated With Adverse Outcomes After Infection With Clostridium difficile.. Inflamm Bowel Dis. 25(4):775-781.
Gogokhia L, Buhrke K, Bell R, Hoffman B, D Brown G, Hanke-Gogokhia C, Ajami NJ, Wong MC, Ghazaryan A, Valentine JF et al..  2019.  Expansion of Bacteriophages Is Linked to Aggravated Intestinal Inflammation and Colitis.. Cell Host Microbe. 25(2):285-299.e8.
Battat R, Duijvestein M, Guizzetti L, Choudhary D, Boland BS, Dulai PS, Parker CE, Nguyen TM, Singh S, Casteele NVande et al..  2019.  Histologic Healing Rates of Medical Therapies for Ulcerative Colitis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.. Am J Gastroenterol. 114(5):733-745.
Ma C, Battat R, Dulai PS, Parker CE, Sandborn WJ, Feagan BG, Jairath V.  2019.  Innovations in Oral Therapies for Inflammatory Bowel Disease.. Drugs. 79(12):1321-1335.